Abstract: Provided herein are inhibitors of GPX4, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the GPX4 inhibitory compounds for the modulation of ferroptosis and treatment of disease.

Abstract: A seal assembly for a container includes a locking assembly and a gateway. The locking assembly includes a body and an elongated cable. The elongated cable extends from a proximal end to a distal end. The proximal end is restrained by the body. The distal end is movable from an unlocked position spaced from the body to a locked position restrained by the body. The gateway is configured for selectively interlocking with the locking assembly. The gateway includes a power supply, a radio communication device, a sensor, and a processor electrically coupled therewith. The processor is configured to operate the radio communication device to transmit a first signal upon detection by the sensor of interlocking of the gateway with the locking assembly, and to transmit a second signal upon detection by the sensor that the elongated cable has been cut. Locking assemblies, gateways, devices and methods are also provided.

Abstract: Provided herein are methods of screening a therapy for induction of ferroptosis, the method comprising: exposing a cell line to a potential therapy; measuring induction of Heme Oxygenase 1 (HMOX1) resulting from the exposing the cell line to the potential therapy; and identifying the potential therapy as passing or failing the screening of the therapy for induction of ferroptosis based on the measuring the induction of HMOX1.

Abstract: Provided herein are methods of functionally linking two or more genetic loci of a genome of a cell sample, the method comprising: exposing the cell sample to a plurality of different stimuli in parallel for a period of time sufficient to elicit a transcriptional response from the cell sample directly or indirectly; performing a transcriptional run-on assay on the cell sample to yield labeled nascent RNA transcripts; isolating the labeled nascent RNA transcripts; preparing a nascent RNA library from the labeled nascent RNA transcripts; sequencing the nascent RNA library to produce sequencing reads and mapping the sequencing reads to a reference genome, wherein the sequencing reads that are mapped represent genomic locations in the cell sample where active transcription was occurring at the end of the period of time; and identifying active enhancers and correlating activity of the active enhancers with the active transcription of the cell samples.

Abstract: Provided herein are methods of identifying a marker for a biological interaction, the method comprising: quantifying genome-wide RNA expression in cells; exposing the cells to a perturbagen for a period of time sufficient to induce the biological interaction in the cells, wherein the induced biological interaction comprises inducing changes in RNA expression in the cells that are exposed to the perturbagen; quantifying genome-wide nascent RNA expression in the cells that were exposed to the perturbagen; calculating a difference in the genome-wide nascent RNA expression between (i) the genome-wide RNA expression in the cells absent the perturbagen and (ii) the genome-wide nascent RNA expression in the cells that were exposed to the perturbagen; and identifying the marker using the calculated difference in the genome-wide nascent RNA expression.

Abstract: This invention encompasses an isolated Bacillus phage AP50 that has one or more nucleotide substitutions in the phage genome, whereby the one or more nucleotide substitutions increase lytic activity of the phage. In addition, the invention encompasses proteins expressed by the phages, compositions containing the proteins and/or the phage as well as methods of using the Bacillus phage AP50 to test for the presence of B. anthracis.